PDS Biotechnology (NASDAQ:PDSB) shares are up on Wednesday as the company announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial of PDS01ADC in the Journal of Clinical Oncology (JCO) Oncology Advances.
Trial Data Show Improved Immune Response In Colorectal Cancer
The published data from the trial indicate that PDS01ADC significantly enhances immune response in colorectal cancer patients who have failed prior treatments.
The stock’s rise follows the publication of findings showing a 78% objective response rate with PDS01ADC versus 35% in a parallel trial without PDS01ADC.
This promising result comes from a study that included 22 patients, with a two-year survival rate exceeding 80% for those treated with PDS01ADC versus 35%.
Progression-Free Survival Remains Unreached
The median progression-free survival (PFS) was not reached at the minimum follow-up of 13.1 months; in the parallel trial without PDS01ADC, the PFS was 8.1 months.
Additional Data From Prostate Cancer Study
Earlier, the company presented encouraging early results from an NCI-led trial investigating PDS01ADC at the AACR special conference on prostate cancer research.
In patients with metastatic castration-resistant prostate cancer, the majority of whom received third-line treatment options, the combination of PDS01ADC and docetaxel demonstrated encouraging median PFS of 9.6 months and a median PSA decline of 40%, with 6 of 16 patients achieving greater than 50% decline.
PDSB Stock Price Activity: PDS Biotechnology shares were up 25.47% at $1.33 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo by Aunt Spray via Shutterstock
Recent Comments